Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer

被引:44
作者
Abdolahi, Mohammad [1 ]
Shahbazi-Gahrouei, Daryoush [1 ]
Laurent, Sophie [2 ]
Sermeus, Corine [2 ]
Firozian, Farzin [3 ]
Allen, Barry J. [4 ]
Boutry, Sebastien [2 ,5 ]
Muller, Robert N. [2 ,5 ]
机构
[1] Isfahan Univ Med Sci, Dept Med Phys & Med Engn, Sch Med, Esfahan, Iran
[2] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, B-7000 Mons, Belgium
[3] Isfahan Univ Med Sci, Dept Pharmaceut, Sch Pharm & Pharmaceut Sci, Esfahan, Iran
[4] Univ New S Wales, Fac Med, Kogarah, NSW 2217, Australia
[5] Ctr Microscopy & Mol Imaging, B-6041 Charleroi, Belgium
关键词
prostate cancer; prostate specific membrane antigen (PSMA); superparamagnetic iron oxide nanoparticles; nanoprobe; magnetic resonance imaging; RANDOMIZED CONTROLLED-TRIALS; MAXIMUM ANDROGEN-BLOCKADE; MEMBRANE ANTIGEN-PSMA; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODIES; NANOPARTICLES; LOCALIZATION; METAANALYSIS; EXPRESSION; CASTRATION;
D O I
10.1002/cmmi.1514
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Carcinoma of the prostate is the most frequent diagnosed malignant tumor in men and is the second leading cause of cancer-related death in this group. The cure rate of prostate cancer is highly dependent on the stage of disease at the diagnosis and early detection is key to designing effective treatment strategies. The objective of the present study is to make a specific MR imaging probe for targeted imaging of cancer cells. We take advantage of the fact that many types of prostate cancer cells express high levels of prostate-specific membrane antigen (PSMA) on their cell surface. The imaging strategy is to use superparamagnetic iron oxide nanoparticles (SPIONs), attached to an antibody (J591) that binds to the extracellular domain of PSMA, to specifically enhance the contrast of PSMA-expressing prostate cancer cells. Conjugation of mAb J591 to commercial SPIONs was achieved using a heterobifunctional linker, sulfo-SMCC. Two types of prostate cancer cell lines were chosen for experiments: LNCaP (PSMA+) and DU145 (PSMA-). MRI and cell uptake experiments demonstrated the high potential of the synthesized nanoprobe as a specific MRI contrast agent for detection of PSMA-expressing prostate cancer cells. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:175 / 184
页数:10
相关论文
共 43 条
[1]  
Artemov D, 2003, CANCER RES, V63, P2723
[2]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[3]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[4]   Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide [J].
Bennett, CL ;
Tosteson, TD ;
Schmitt, B ;
Weinberg, PD ;
Ernstoff, MS ;
Ross, SD .
PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (01) :4-8
[5]  
Candas B, 2000, PROSTATE, V45, P19
[6]   Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase [J].
Carter, RE ;
Feldman, AR ;
Coyle, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :749-753
[7]   Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens [J].
Caubet, JF ;
Tosteson, TD ;
Dong, EW ;
Naylon, EM ;
Whiting, GW ;
Ernstoff, MS ;
Ross, SD .
UROLOGY, 1997, 49 (01) :71-78
[8]  
Chang SS, 1999, CANCER RES, V59, P3192
[9]  
DeGrado TR, 2001, CANCER RES, V61, P110
[10]   Molecular imaging of prostate cancer [J].
Emonds, K. M. ;
Swinnen, J. V. ;
Mortelmans, L. ;
Mottaghy, F. M. .
METHODS, 2009, 48 (02) :193-199